Aura Biosciences (NASDAQ:AURA) Receives “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Aura Biosciences (NASDAQ:AURA) in a research note issued to investors on Monday morning,Benzinga reports. HC Wainwright currently has a $22.00 price objective on the stock.

Separately, Lifesci Capital upgraded shares of Aura Biosciences to a “strong-buy” rating in a report on Friday, January 31st. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $23.00.

Aura Biosciences Stock Performance

Aura Biosciences stock opened at $7.00 on Monday. The firm has a market capitalization of $349.66 million, a PE ratio of -4.05 and a beta of 0.30. Aura Biosciences has a one year low of $6.33 and a one year high of $12.38. The stock’s 50 day moving average price is $7.65 and its 200 day moving average price is $8.66.

Aura Biosciences (NASDAQ:AURA) last posted its earnings results on Wednesday, March 26th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.09). On average, analysts forecast that Aura Biosciences will post -1.66 earnings per share for the current fiscal year.

Insider Activity at Aura Biosciences

In related news, insider Los Pinos Elisabet De sold 15,955 shares of Aura Biosciences stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $7.67, for a total value of $122,374.85. Following the completion of the transaction, the insider now directly owns 304,692 shares in the company, valued at approximately $2,336,987.64. This trade represents a 4.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 23,045 shares of company stock valued at $177,242 over the last ninety days. Corporate insiders own 5.40% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of AURA. Long Focus Capital Management LLC increased its holdings in shares of Aura Biosciences by 123.9% in the 4th quarter. Long Focus Capital Management LLC now owns 2,537,774 shares of the company’s stock valued at $20,861,000 after acquiring an additional 1,404,228 shares during the last quarter. Vanguard Group Inc. increased its stake in Aura Biosciences by 6.2% during the fourth quarter. Vanguard Group Inc. now owns 1,917,730 shares of the company’s stock valued at $15,764,000 after purchasing an additional 112,296 shares during the last quarter. Franklin Resources Inc. raised its holdings in shares of Aura Biosciences by 3.2% during the fourth quarter. Franklin Resources Inc. now owns 1,723,063 shares of the company’s stock worth $14,164,000 after purchasing an additional 54,103 shares during the period. Levin Capital Strategies L.P. raised its holdings in shares of Aura Biosciences by 169.1% during the fourth quarter. Levin Capital Strategies L.P. now owns 1,247,619 shares of the company’s stock worth $10,255,000 after purchasing an additional 783,984 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of Aura Biosciences by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 1,012,799 shares of the company’s stock worth $8,327,000 after buying an additional 3,972 shares during the last quarter. Institutional investors own 96.75% of the company’s stock.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.